Virtual clinical trials have some advantages, but they also come with their share of challenges. This article examines the benefits and challenges of decentralized clinical trials and the impact on the underrepresentation of minority groups. This article also explores the challenges associated with remote measurement and the delivery of experimental medicines via the mail.
Contents
Challenges of conducting virtual clinical trials
Conducting virtual clinical trials has a number of advantages over traditional clinical trials, but it does have some challenges. One of these challenges is the fact that virtual communication cannot replace face-to-face interaction. Furthermore, the lack of human contact may make participants uneasy, especially those who are elderly. Virtual clinical trials are also less expensive because the investigator does not need to pay for a physical site, full staff, or storage facilities.
Disparity is often a major barrier for participation in clinical trials. It can affect both the selection of subjects and the research and dissemination of results. For example, while African Americans constitute 12 percent of the US population, they participate in less than 5% of clinical trials. Moreover, Hispanics account for nearly 16% of the population, yet only 2% of clinical trials are conducted on them. This discrepancy is compounded by the extra costs for recruiting diverse populations.
Challenges of conducting decentralized clinical trials
While decentralized clinical trials are a great way to bring cutting-edge treatments to underserved communities, they are not without their challenges. For instance, many people live far away from clinical trial sites, making it impossible to make in-person visits with the research team. Patients may be unable to afford to travel, or they may not have reliable Internet access.
To combat these challenges, decentralized clinical trials must have a dynamic design that can adapt to changes in the clinical study. This means that the drug formulation, IND approval, study start-up, and patient-visit schedules need to be flexible and able to accommodate any changes. They also need to be able to meet ever-changing quality and regulatory standards and maintain patient safety.
One of the most important aspects of conducting decentralized clinical trials is the data collection. Unlike traditional clinical trials, decentralized clinical trials can collect daily data from patients. This helps researchers understand how a drug works in the real world. It also helps them obtain insights that would not be possible in a traditional clinical trial setting. For example, participants in a decentralized trial may experience varying blood pressure due to stress and temperature fluctuations due to external factors.
Benefits of conducting virtual clinical trials
Conducting virtual clinical trials has a number of benefits over traditional trials, including a decrease in operating costs, increased patient retention, and greater access to medical care. It is also a more comfortable and convenient way to recruit patients because patients can participate from home. Virtual trials also allow physicians to treat more patients because they do not have to drive to multiple locations to complete the study.
Virtual trials are geared towards increasing participation by underrepresented populations. In addition to addressing special considerations, virtual trials can help improve inclusion rates by establishing relationships with the community. These trials can also generate data on access and equity. As a result, specific disease areas can be addressed immediately.
Inclusion is a critical issue in clinical trials, as participants come from diverse communities. Inclusion rates are much lower for populations living in regions outside the US. In addition, decentralized approaches often use home health providers or local clinics to recruit patients. As a result, many potential participants do not want to travel long distances to take part in a traditional study. Moreover, many participants are put off by the long waiting times. Geographic limitations are particularly pronounced among groups that are traditionally excluded from clinical trials.